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Abstract	
Background:	A	critical	problem	in	the	clinical	management	of	prostate	cancer	is	that	it	is	
highly	 heterogeneous.	 Accurate	 prediction	 of	 individual	 cancer	 behaviour	 is	 therefore	
not	achievable	at	the	time	of	diagnosis	leading	to	substantial	overtreatment.	It	remains	
an	enigma	that,	in	contrast	to	breast	cancer,	unsupervised	analyses	of	global	expression	
profiles	 has	 not	 currently	 defined	 robust	 categories	 of	 prostate	 cancer	 with	 distinct	
clinical	outcomes.		
Objective:		To	devise	a	novel	classification	framework	for	human	prostate	cancer	based	
on	unsupervised	mathematical	approaches.		
Design,	 Setting,	 and	 Participants:	 Our	 analyses	 are	 based	 on	 the	 hypothesis	 that	
previous	attempts	to	classify	prostate	cancer	have	been	unsuccessful	because	individual	
samples	 of	 prostate	 cancer	 frequently	 have	 heterogeneous	 compositions.	 To	 address	
this	 issue	 we	 applied	 an	 unsupervised	 Bayesian	 procedure	 called	 Latent	 Process	
Decomposition	 to	 four	 independent	 prostate	 cancer	 transcriptome	 datasets	 obtained	
using	 samples	 from	 prostatectomy	 patients	 and	 containing	 between	 78	 and	 182	
participants.		
Outcome	 Measurements	 and	 Statistical	 Analysis:	 	 Biochemical	 failure	 was	 assessed	
using	log-rank	analysis	and	Cox	regression	analysis.	
Results	 and	 Limitations:	 Application	 of	 LPD	 identified	 a	 common	 process	 in	 all	 four	
independent	 datasets	 examined.	 Cancers	 assigned	 to	 this	 process	 (designated	 DESNT	
cancers)	are	characterized	by	low	expression	of	a	core	set	of	45	genes,	many	encoding	
proteins	 involved	 in	 the	 cytoskeleton	machinery,	 ion	 transport	 and	 cell	 adhesion.	 For	
the	 three	datasets	with	 linked	PSA	 failure	data	 following	prostatectomy,	patients	with	
DESNT	 cancer	 exhibited	 poor	 outcome	 relative	 to	 other	 patients	 (P	=	2.65x10-5,	
P	=	4.28x10-5,	 and	 P	=	2.98x10-8).	 When	 these	 three	 datasets	 were	 combined	 the	
independent	 predictive	 value	 of	 DESNT	 membership	 was	 P	=	1.61x10-7	 compared	 to	
P	=	1.00x10-5	for	Gleason	 sum.	A	 limitation	of	 the	 study	 is	 that	 only	 prediction	of	 PSA	
failure	was	examined.		
Conclusions:	Our	results	demonstrate	the	existence	of	a	novel	poor	prognosis	category	
of	 human	 prostate	 cancer	 and	 will	 assist	 in	 the	 targeting	 of	 therapy,	 helping	 avoid	
treatment-associated	morbidity	in	men	with	indolent	disease.																																																																																				
	
Patient	 Summary:	 Prostate	 cancer,	 unlike	 breast	 cancer,	 does	 not	 have	 a	 robust	
classification	 framework.	We	 propose	 that	 this	 failure	 has	 occurred	 because	 prostate	
cancer	 samples	 selected	 for	 analysis	 frequently	 have	 heterozygous	 compositions	
(individual	 samples	 are	 made	 up	 of	 many	 different	 parts	 that	 each	 have	 different	
characteristics).	Applying	a	mathematical	approach	that	can	overcome	this	problem	we	
identify	a	novel	poor	prognosis	category	of	human	prostate	cancer	called	DESNT.		
Keywords:	poor	prognosis	category;	novel	prostate	cancer	classification;	DESNT	prostate	
cancer;	Latent	Process	Decomposition	
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	1.	Introduction	
Risk	categories	based	on	PSA,	Gleason	score	and	Clinical	Stage	that	predict	PSA	failure[1]	
underpin	the	treatment	of	localized	prostate	cancer,	as	illustrated,	for	example,	by	the		
UK	 National	 Institute	 for	 Health	 and	 Care	 Excellence	 guidelines[2].	 	 Attempts	 to	
improved	 risk	 stratification	 have	 been	made	 by	 the	 development	 of	 prognostic	 tests,	
such	 as	 Prolaris[3],	 Oncotype	 DX[4]	 and	 Decipher[5].	 	 Most	 such	 expression-based	
prognostic	signatures	for	prostate	cancer	have	in	common	that	they	were	derived	using	
supervised	 steps,	 involving	 either	 comparisons	 of	 aggressive	 and	 non-aggressive	
disease[5,6]	 or	 the	 selection	 of	 genes	 representing	 specific	 biological	 functions[3,7,8].	
Alternatively	 expression	 biomarkers	 may	 be	 linked	 to	 the	 presence	 of	 somatic	 copy	
number	 variations[9].	 In	 contrast,	 for	 breast	 cancer,	 unsupervised	 analysis	 of	
trancriptome	 profiles,	 using	 approaches	 such	 as	 hierarchical	 clustering	 has	 identified	
robust	disease	categories	that	have	distinct	clinical	outcomes	and	that	require	different	
treatment	strategies[10].		
Our	hypothesis	 is	 that	completely	unsupervised	classification	of	prostate	cancer	based	
on	 transcriptome	 data	 has	 not	 been	 successful	 previously[9,11]	 because	 individual	
samples	of	prostate	cancer	can	contain	more	than	one	contributing	lineage[12,13]	and	
frequently	 have	 heterogeneous	 compositions[14-16].	 To	 test	 this	 idea,	 in	 the	 current	
study,	 we	 applied	 Latent	 Process	 Decomposition[17,18]	 (LPD).	 Based	 on	 the	 latent	
Dirichlet	allocation	method[19],	LPD	assesses	the	structure	of	a	dataset	in	the	absence	
of	 knowledge	 of	 clinical	 outcome	 or	 biological	 role[17].	 In	 contrast	 to	 standard	
unsupervised	 clustering	 models	 (e.g.	 k-means	 and	 hierarchical	 clustering),	 individual	
cancers	 are	 not	 assigned	 to	 a	 single	 cluster:	 instead	 gene	 expression	 levels	 in	 each	
cancer	are	modeled	via	combinations	of	 latent	processes.	 	We	previously	used	LPD	to	
confirm	 the	 presence	 of	 basal	 and	 ERBB2	 overexpressing	 categories	 in	 breast	 cancer	
datasets[17],	 and	 to	 show	 that,	 based	 on	 blood	 expression	 profiles,	 patients	 with	
advanced	prostate	cancer	can	be	stratified	into	two	clinically	distinct	groups[20].		
2.	Materials	and	Methods	
	
2.1	The	CancerMap	dataset		
Fresh	 prostate	 cancer	 specimens	 were	 obtained	 and	 processed	 from	 a	 systematic	 series	 of	
patients	who	had	undergone	a	prostatectomy	at	the	Royal	Marsden	NHS	Foundation	Trust	and	
Addenbrooke's	 Hospital,	 Cambridge	 as	 previously	 described[9,21,22].	 	 The	 relevant	 local	
Research	 Ethics	 Committee	 approved	was	obtained.	 Expression	profiles	were	determined	 and	
data	was	 processed	 as	 previously	 described[22]	 using	 1.0	 Human	 Exon	 ST	 arrays	 (Affymetrix,	
Santa	Clara,	CA,	USA)	according	to	the	manufacturer’s	instructions.	Data	are	available	from	the	
Gene	Expression	Omnibus:	GSE	 (data	 to	be	 released	on	publication).	 	CancerMap	patients	did	
not	receive	neo-adjuvant	treatment.		
	
2.2	Additional	Transcriptome	Datasets	
We	 analysed	 five	 prostate	 cancer	 microarray	 datasets	 that	 will	 be	 referred	 to	 as:	 MSKCC,	
CancerMap,	 CamCap,	 Stephenson	 and	 Klein.	 The	 data	 used,	 platforms	 and	 location	 of	 clinical	
data	 are	 presented	 in	 Fig.	 1b.	 Each	 dataset	 was	 obtained	 using	 samples	 from	 prostatectomy	
patients.	CamCap	dataset	used	in	our	study	was	produced	combining	Illumina	HumanHT-12	V4.0	
expression	beadchip	(bead	microarray)	datasets	(GEO:	GSE70768	and	GSE70769)	obtained	from	
two	 prostatectomy	 series	 (Cambridge	 and	 Stockholm)	 and	 consisted	 of	 147	 cancer	 and	 73	
normal	samples[9].	The	CamCap	and	CancerMap	datasets	have	in	common	40	patients	and	thus	
are	not	 independent.	One	RNAseq	dataset	consisting	of	333	prostate	cancers	from	The	Cancer	
Genome	Atlas	was	analysed	which	we	 refer	 to	 as	 TCGA[13].	 The	 counts	per	 gene	 supplied	by	
TCGA	were	used.	
	
2.3	Latent	Process	Decomposition	
Latent	process	decomposition	 (LPD)	 [17,18],	 an	unsupervised	Bayesian	approach,	was	used	 to	
classify	samples	 into	subgroups	called	processes.	We	selected	the	500	probesets	with	greatest	
variance	across	the	MSKCC	dataset	for	use	in	LPD.	These	probesets	map	to	492	genes.	For	each	
dataset	 all	 probesets	 that	 map	 to	 these	 genes	 were	 used	 in	 LPD	 analyses	 (CancerMap:	 507	
probesets,	CamCap:483,	Stephenson:	609).		
	 LPD	can	objectively	assess	the	most	likely	number	of	processes.	We	assessed	the	hold-
out	validation	 log-likelihood	of	 the	data	computed	at	various	number	of	processes	and	used	a	
combination	 of	 both	 the	 uniform	 (equivalent	 to	 a	 maximum	 likelihood	 approach)	 and	 non-
uniform	 (MAP	 approach)	 priors	 to	 choose	 the	 number	 of	 processes.	 For	 robustness,	 we	
restarted	LPD	100	times	with	different	seeds,	for	each	dataset.	Out	of	the	100	runs	we	selected	
a	representative	run	that	was	used	for	subsequent	analysis.	The	representative	run,	was	the	run	
with	 the	survival	 log-rank	p-value	closest	 to	 the	mode.	For	 the	Klein	dataset,	 for	which	we	do	
not	have	clinical	data,	we	used	the	hold-out	log-likelihood	from	LPD	instead.	
	
2.4	Statistical	Tests	
All	statistical	tests	were	performed	in	R	version	3.2.2	(https://www.r-project.org/).	Correlations	
between	 the	 expression	 profiles	 between	 two	 datasets	 for	 a	 particular	 gene	 set	 and	 sample	
subgroup	were	calculated	as	follows:	
1.	 For	each	gene	we	select	one	probeset	at	random;	
2.	 for	each	probeset	we	transformed	its	distribution	across	all	samples	to	a	standard	normal	
distribution;		
3.	 the	 average	 expression	 for	 each	 probeset	 across	 the	 samples	 in	 the	 subgroup	 is	
determined,	to	obtain	an	expression	profile	for	the	subgroup.		
4.	 the	 Pearson’s	 correlation	 between	 the	 expression	 profiles	 of	 the	 subgroups	 in	 the	 two	
datasets	is	determined.		
Differentially	expressed	probesets	were	identified	using	a	moderated	t-test	implemented	in	the	
limma	R	package[23].	Genes	are	considered	significantly	differentially	expressed	if	the	adjusted	
p-value	was	below	0.01	(p	values	adjusted	using	the	False	Discovery	Rate).		
	 Survival	analyses	were	performed	using	Cox	proportional	hazards	models,	 the	 log-rank	
test,	and	Kaplan-Meier	estimator,	with	biochemical	recurrence	after	prostatectomy	as	the	end	
point.	 When	 several	 samples	 per	 patient	 were	 available,	 only	 the	 sample	 with	 the	 highest	
proportion	of	tumour	tissue	was	used.	Multivariate	survival	analyses	were	performed	with	the	
clinical	 covariates	 Gleason	 grade	 (≤7	 and	 >7),	 pathological	 stage	 (T1/T2	 and	 T3/T4)	 and	 PSA	
levels	 (≤10	and	>10).	We	modelled	 the	 variables	 that	did	not	 satisfy	 the	proportional	 hazards	
assumption	(T-stage	in	MSKCC),	as	a	product	of	the	variable	with	the	heavyside	function:	
	 	
where	 t0	 is	 a	 time	 threshold.	 The	 multiplication	 of	 a	 predictor	 with	 the	 heavyside	 function,	
divides	the	predictor	into	time	intervals	for	which	the	extended	Cox	model	computes	different	
hazard	ratios.	Before	carrying	out	multivariate	analyses	we	assessed	collinearity	between	
the	DESNT	predictor	and	the	other	 traditional	 indicators.	To	do	 this	we	calculated	 the	
variance	 inflation	 factor	 (VIF)	 for	 each	 covariate	 in	 each	 model.	 VIF	 varied	 between	
1.005241	and	1.461661,	suggesting	a	very	weak	correlation	between	the	predictors.	
	
2.5	Driving	an	optimal	predictor	of	DESNT	membership	
To	derive	an	optimal	predictor	of	DESNT	membership	the	datasets	were	prepared	so	that	they	
were	 comparable:	 probes	 were	 only	 retained	 if	 the	 associated	 gene	 was	 found	 in	 every	
microarray	 platform,	 only	 one	 randomly	 chosen	 probe	 was	 retained	 per	 gene	 and	 the	 batch	
effects	adjusted	using	the	ComBat	algorithm[24].	The	MSKCC	dataset	was	used	as	the	training	
set	 and	 other	 datasets	 as	 test	 sets.	 	 Gene	 selection	was	 performed	 using	 regularized	 general	
linear	model	approach	(LASSO)	implemented	in	the	glmnet	R	package[25],	starting	with	all	genes	
that	 were	 significantly	 up	 or	 down	 regulated	 in	 DESNT	 in	 at	 least	 two	 of	 the	 total	 of	 five	
microarray	dataset	(1669	genes).	LASSO	was	run	100	times	and	only	genes	that	were	selected	in	
at	 least	25%	of	 runs	were	retained.	The	optimal	predictor	was	then	derived	using	the	random	
forest	model[26]	 implemented	 in	 the	 randomForest	 R	 package[27].	 Default	 parameters	 were	
used,	 apart	 from	 the	 number	 of	 trees	 were	 set	 to	 10001	 and	 the	 class	 size	 imbalance	 was	
adjusted	for	by	down-sampling	the	majority	class	to	the	frequency	of	the	minority	class	
	
	
3.	Results		
3.1	Identification	of	the	DESNT	cancer	category	
Four	 independent	 transcriptome	 datasets	 (designated	 MSKCC[11],	 CancerMap,	
Klein[28],	 and	 Stephenson[29],	 Fig.	 1b)	 obtained	 from	prostatectomy	 specimens	were	
analyzed.	 LPD	 was	 performed	 using	 between	 3	 and	 8	 underlying	 latent	 processes	
contributing	to	the	overall	expression	profile	as	indicated	from	log-likelihood	plots	(Fig.	
1b,	 Supplemental	 Fig.	 1).	 Following	 the	 independent	 decomposition	 of	 each	 dataset,	
cancers	were	assigned	 to	 individual	processes	based	on	 their	highest	pi	 value	 yielding	
the	 results	 shown	 in	 Fig.	 1a	 and	 Supplemental	 Fig.	 2.	 pi	 is	 the	 contribution	 of	 each	
process	 “i"	 to	 the	 expression	 profile	 of	 an	 individual	 cancer:	 sum	 of	 pi	 over	 all	
processes=1.			
	
Searching	for	relationships	between	the	decompositions,	a	single	process	was	identified	
that,	based	on	correlations	of	gene	expression	levels,	appeared	to	be	common	across	all	
four	 datasets	 (Fig.	 1c).	 To	 further	 investigate	 this	 association,	 for	 each	 dataset,	 we	
identified	 genes	 that	 were	 expressed	 at	 significantly	 lower	 or	 higher	 levels	 (P	<	0.01	
after	 correction	 for	 False	 Discovery	 Rate)	 in	 the	 cancers	 assigned	 to	 this	 process	
compared	to	all	other	cancers	from	the	same	dataset.	This	unveiled	a	shared	set	of	45	
genes,	all	with	 lower	expression	(Fig.	2a,	Supplemental	Table	1).	Many	of	 the	proteins	
encoded	 by	 these	 45	 core	 genes	 are	 components	 of	 the	 cytoskeleton	 or	 regulate	 its	
g(t) = 1,  if t ≥ t0
0,  otherwise
⎧
⎨
⎪
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dynamics,	while	others	are	involved	in	cell	adhesion	and	ion	transport	(Fig.	2b).	Eleven	
of	 the	45	genes	were	members	of	published	prognostic	signatures	 for	prostate	cancer	
(Fig.	 2c,	 Supplemental	 Data	 File	 1).	 For	 example	MYLK,	 ACTG2,	 and	 CNN1	 are	 down-
regulated	 in	a	signature	 for	cancer	metastasis[30],	while	 lower	expression	of	 	TPM2	 is	
associated	with	poorer	outcome	as	part	of	 the	Oncotype	DX	signature[4].	The	cancers	
assigned	 to	 this	 common	process	are	 referred	 to	as	 “DESNT”	 (latin	DEScenduNT,	 they	
descend).			
	
3.2	Patients	with	DESNT	cancers	exhibit	poor	prognosis	
Using	 linked	 clinical	 data	 available	 for	 the	 MSKCC	 expression	 dataset	 we	 found	 that	
patients	 with	 DESNT	 cancer	 exhibited	 poor	 outcome	 when	 compared	 to	 patients	
assigned	 to	 other	 processes	 (P	=	2.65x10-5,	 Log-rank	 test,	 Fig.	 1d).	 Validation	 was	
provided	in	two	further	datasets	where	PSA	failure	data	following	prostatectomy	were	
available	 (Fig.	 1d):	 for	 both	 the	 Stephenson	 and	 CancerMap	 datasets	 patients	 with	
DESNT	cancer	exhibited	poor	outcome	(P	=	4.28x10-5	and	P	=	2.98x10-8	respectively).	The	
number	of	cancers	in	each	group	is	indicated	in	the	bottom	right	corner	of	each	Kaplan-
Meier	 plot.	 The	 number	 of	 patients	 with	 PSA	 failure	 is	 indicated	 in	 parentheses.	 In	
multivariate	 analysis,	 including	 Gleason	 sum,	 Stage	 and	 PSA,	 assignment	 as	 a	 DESNT	
cancer	 was	 an	 independent	 predictor	 of	 poor	 outcome	 in	 the	 Stephenson	 and	
CancerMap	datasets	 (P	=	1.83x10-4	and	P	=	3.66x10-3,	Cox	regression	model)	but	not	 in	
the	MSKCC	dataset	(P	=	0.327)	(Table	1,	Supplemental	Fig.	3).	When	the	three	datasets	
were	 combined	 the	 independent	 predictive	 value	 of	 DESNT	 membership	 was	
P	=	1.61x10-7	 (Supplemental	 Fig.	 3),	 compared	 to	 P	=	1.00x10-5	 for	 Gleason	 sum.	
Including	surgical	margin	status	in	the	multivariate	analysis	had	little	influence	on	these	
values	 giving	P	=3.63x10-7	 for	 DESNT	 compared	 to	P	=	1.80x10-5	for	 Gleason	 Sum.	 The	
combined	 multivariate	 model	 is	 a	 significant	 improvement	 over	 a	 baseline	 Cox	
proportional	hazard	ratio	model	containing	Gleason,	PSA	and	Clinical	Stage	(p=9.528x10-
7;	 likelihood	 ratio	 test).	 The	 poor	 prognosis	 DESNT	 process	 was	 also	 identified	 in	 the	
CamCap	dataset[9]	(Table	1,	Supplemental	Fig.	3	and	4),	which	was	excluded	from	the	
above	 analysis	 because	 it	 was	 not	 independent:	 there	 is	 a	 substantial	 overlap	 with	
cancers	included	in	CancerMap	(Fig.	1b).		
	
3.3		A	random	forest	classifier	for	identifying	DESNT	cancer	
We	 wished	 to	 develop	 a	 classifier	 that,	 unlike	 LPD,	 was	 not	 computer	 processing	
intensive	and	that	could	be	applied	both	to	a	wider	range	of	datasets	and	to	individual	
cancers.	 1669	 genes	 with	 significantly	 altered	 expression	 between	 DESNT	 and	 non-
DESNT	 cancers	 in	 at	 least	 two	 datasets	 were	 selected	 for	 analysis.	 A	 LASSO	 logistic	
regression	model	was	 used	 to	 identify	 genes	 that	were	 the	 best	 predictors	 of	 DESNT	
membership	 in	 the	 MSKCC	 dataset	 leading	 to	 the	 selection	 of	 a	 set	 of	 20	 genes	
(Supplemental	 Table	 2),	which	 had	 a	 one	 gene	overlap	 (ACTG2)	 to	 the	 45	 genes	with	
significantly	lower	expression	in	DESNT	cancers.	Using	random	forest	(RF)	classification	
these	 20	 genes	 provided	 high	 specificity	 and	 sensitivity	 for	 predicting	 that	 individual	
cancers	were	DESNT	in	both	the	MSKCC	training	dataset	and	in	three	validation	datasets	
(Supplemental	 Fig.	 5).	 For	 the	 two	 validation	 datasets	 (Stephenson	 and	 CancerMap)	
with	 linked	 PSA	 failure	 data	 the	 predicted	 cancer	 subgroup	 exhibited	 poorer	 clinical	
outcome	 in	 both	 univariate	 and	multivariate	 analyses,	 in	 agreement	 with	 the	 results	
observed	using	LPD	(Table	1,	Fig.	3).		
	
3.4	DESNT	cancers	in	the	The	Cancer	Genome	Atlas	dataset	
When	RF	classification	was	applied	to	RNAseq	data	from	333	prostate	cancers	described	
by	 The	 Cancer	 Genome	 Atlas	 (TCGA)[13]	 a	 patient	 subgroup	 was	 identified	 that	 was	
confirmed	 as	 DESNT	 based	 on:	 (i)	 correlations	 of	 gene	 expression	 levels	 with	 DESNT	
cancer	groups	in	other	datasets	(Supplemental	Fig	6);	(ii)	demonstration	of	overlaps	of	
differentially	 expressed	 genes	 between	 DESNT	 and	 non-DESNT	 cancers	 with	 the	 core	
down-regulated	gene	 set	 (45/45	genes);	 and	 (iii)	 its	 poorer	 clinical	 outcome	based	on	
PSA	failure	(P	=	5.4x10-4)	compared	to	non-DESNT	patients	(Table	1,	Fig.	3e).	
	
For	 the	 TCGA	dataset,	we	 failed	 to	 find	 correlations	 between	 assignment	 as	 a	DESNT	
cancer	and	the	presence	of	any	specific	genetic	alteration	(P	>	0.05	after	correction	for	
False	Discovery	Rate,	χ²	test,	Fig.	4).		Of	particular	note	there	was	no	correlation	to	ETS-
gene	status	(P,	=	0.136,	χ²	test,	Fig.	4).	A	lack	of	correlation	between	DESNT	cancers	and	
ERG-gene	 rearrangement,	 determined	 using	 the	 fluorescence	 in	 situ	 hybridization	
break-apart	assay[31],	was	confirmed	using	CancerMap	samples	(LPD-DESNT,	P	=	0.549;	
RF-DESNT,	P	=	0.2623,	 χ²	 test:	DESNT	 cancers	 identified	by	 LPD	and	by	RF	 approaches	
are	 referred	 to	 respectively	 as	 LPD-DESNT	 and	 RF-DESNT).	 These	 observations	 are	
consistent	 with	 the	 lack	 of	 correlation	 between	 ERG	 status	 and	 clinical	 outcome[32],	
although	 different	 views	 on	 the	 relationship	 between	 ERG-gene	 status	 and	 clinical	
outcome	have	been	expressed[33].	 	Since	ETS-gene	alteration,	 found	 in	around	half	of	
prostate	 cancers[13,31],	 is	 considered	 to	 be	 an	 early	 step	 in	 prostate	 cancer	
development[15,34]		it	is	likely	that	changes	involved	in	the	generation	of	DESNT	cancer	
represent	a	later	event	that	is	common	to	both	ETS-positive	and	ETS-negative	cancers.	
For	RF-DESNT	cancers	 in	 the	TGCA	series	many	of	 the	45	core	genes	exhibited	altered	
levels	 of	 CpG	 gene	 methylation	 compared	 to	 non-RF-DESNT	 cancers	 (Supplemental	
Table	3)	suggesting	a	possible	role	in	controlling	gene	expression.		Supporting	this	idea,	
for	sixteen	of	the	45	core	genes	epigenetic	down-regulation	in	human	cancer	has	been	
previously	 reported,	 including	 six	 genes	 in	 prostate	 cancer	 (CLU,	 DPYSL3,	 GSTP1,	
KCNMA1,	SNAI2,	 and	SVIL)	 (Fig	2b,	 Supplemental	 Table	1).	CpG	methylation	of	 five	of	
the	genes	(FBLN1,	GPX3,	GSTP1,	KCNMA1,	TIMP3)	has	previously	been	linked	to	cancer	
aggression.		
	
4.	Discussion	
Evidence	 from	 The	 European	 Randomized	 study	 of	 Screening	 for	 Prostate	 Cancer	
demonstrates	that	PSA	screening	can	reduce	mortality	from	prostate	cancer	by	21%[35].	
However,	 a	 critical	 problem	 is	 that	 the	 progression	 of	 prostate	 cancer	 is	 highly	
heterogeneous[36,37]	and	PSA	screening	leads	to	the	detection	of	up	to	50%	of	cancers	
that	 are	 clinically	 irrelevant[38,39]:	 that	 is	 cancers	 that	 would	 never	 have	 caused	
symptoms	 in	 a	man’s	 lifetime	 in	 the	 absence	 of	 screening.	 Unsupervised	 analyses	 of	
breast	 cancer	 datasets	 using	 hierarchical	 clustering	 previously	 revealed	 the	 existence	
basal,	 ERBB2-overexpressing	 and	 luminal	 cancer	 categories[10].	 This	 mathematical	
approach	 has	 not	 proven	 successful	 when	 applied	 to	 prostate	 cancer	 microarray	
datasets[9,11].	However	in	our	study	the	use	of	LPD,	an	unsupervised	method	that	takes	
into	 account	 the	 issue	of	 cancer	heterogeneity,	 has	 revealed	 the	existence	of	 a	 novel	
category	 of	 prostate	 cancer,	 designated	 DESNT,	 common	 across	 all	 datasets.	 The	
subsequent	linking	to	clinical	data	revealed	that	DESNT	cancers	exhibit	poor	prognosis.		
It	was	notable	 that	membership	of	 the	DESNT	cancer	groups	was	not	an	 independent	
predictor	of	clinical	outcome	in	the	MSKCC	dataset.	It	is	possible	that	the	difference	may	
simply	reflect	statistical	variation	since	the	size	of	the	DESNT	group	in	several	datasets	
was	 small	 (MSKCC,	 13%;	 CancerMap,	 8%;	 Stephenson,	 31%;	 Klein,	 23%).	 Critically,	
however,	 when	 the	 datasets	 with	 linked	 clinical	 data	 were	 combined	 DESNT	
membership	 remained	 an	 independent	 predictor	 of	 clinical	 outcome.	 We	 failed	 to	
detect	systematic	differences	between	MSKCC	and	other	datasets	used	 in	multivariate	
analyses	(Supplemental	Fig.	3h).	
	
We	 have	 not,	 in	 this	 study,	 investigated	 the	 biological	 function	 and	 mechanisms	 of	
alterations	 of	 expression	 of	 the	 45	 core	 genes.	 However	 gene	 down-regulation	
mediated	by	CpG	methylation	is	well	documented	in	human	cancer,	as	is	the	association	
of	CpG	methylation	of	single	genes	with	aggressive	cancer	behavior	(Supplemental	Table	
1).	 	 The	 results	 found	 for	 DESNT	 cancers	 are	 consistent	with	 these	 observations,	 but	
would	suggest	that	it	is	the	combine	under	expression	of	multiple	genes	that	represents	
a	critical	determinant	of	cancer	progression	and	aggression.	Several	of	the	genes	found	
to	 have	 lower	 expression	 in	 DESNT	 cancer	 (ACTA2,	 CNN1,	 LMOD1)	 encode	 proteins	
primarily	 expressed	 in	 smooth	muscle	 cells	 or	myofibroblast,	 indicative	 of	 an	 altered	
tumour-stromal	environment.		We	failed	to	find	a	correlation	between	stromal	content	
and	clinical	outcome	in	the	CamCap	and	CancerMap	datasets	(Fig.	2).	However	this	does	
not	 exclude	 the	 possibility	 that	 DESNT	 cancers	 themselves	 may	 have	 lower	 stromal	
content,	in	part	explaining	the	lower	expression	of	these	genes.		
Other	under-expressed	genes	encode	components	of	the	actin	cytoskeleton	or	regulate	
its	dynamics	(e.g.	MLCK,	MYL9,	ACTN1,	and	TNS1).	Increased	malignancy	may	correlate	
with	 increased	 cell	 migratory	 behaviour,	 which	 in	 turn	 can	 involve	 deployment	 of	
particular	types	of	cell	adhesion	and	cytoskeletal	machinery[40].		A	high	dependency	on	
actomyosin	 contractility	 is	 recognised	 as	 a	 hallmark	 of	 amoeboid	 movement.	 Down-
regulation	 of	 these	 genes	 in	DESNT	 cancers	would	 argue	 against	 its	 involvement.	 The	
lower	 expression	 of	 focal	 adhesion	 components	 such	 as	 integrin	 α5	 (ITGA5),	 vinculin	
(VCL)	 and	 integrin-linked	 kinase	 (ILK),	 would	 also	 argue	 against	 involvement	 of	
"mesenchymal"	type	migration,	which	is	dependent	on	these	classes	of	genes[40].		It	is	
thus	 possible	 that	 the	 observed	 alterations	 may	 support	 involvement	 of	 collective	
migration	or	expansive	growth	phenotypes[40].		
Notably,	we	failed	to	find	any	relationship	between	DESNT	cancers	and	either	CNV	(copy	
number	 variant)	 signatures	 (Lalonde	 et	 al.	 and	 Ross-Adams	 et	 al.	 in	 Fig.	 2c)	 or	 DNA	
repair	gene	alterations	 (Fig.	4).	 	Assignment	of	cancers	within	 the	DESNT	classification	
framework	 together	with	 the	 use	 of	 standard	 clinical	 indicators	 (Stage,	 Gleason	 sum,	
PSA),	 CNV	 signatures[11],	 expression	 biomarkers	 such	 as	 Prolaris[3], Decipher[5],	 and	
Oncotype	 DX[4]	 identified	 in	 supervised	 analyses	 and	 urine	 biomarkers[41],	 should	
significantly	enhance	the	ability	 identify	patients	whose	cancers	should	be	targeted	by	
radical	 therapies,	 avoiding	 the	 side	 effects	 of	 treatment,	 including	 impotence,	 in	men	
with	non-aggressive	disease.	 In	 future	studies	we	are	 focusing	on	 the	development	of	
both	LPD	and	RF	based	tests	that	can	be	used	to	detect	DESNT	cancer	in	biopsy	tissue	in	
a	clinical	setting.	
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FIGURES	AND	TABLES	
	
Figure	1.	Latent	Process	Decomposition	(LPD),	gene	correlations	and	clinical	outcome.	a,	LPD	analysis	of	
Affymetrix	 expression	 data	 from	 the	 MSKCC	 datasets	 divided	 the	 samples	 into	 eight	 processes,	 each	
represented	here	by	a	bar	chart.	Samples	are	 represented	 in	all	eight	processes	and	height	of	each	bar	
corresponds	to	the	proportion	(pi)	of	the	signature	that	can	be	assigned	to	each	LPD	process.	Samples	are	
assigned	to	the	LPD	group	in	which	they	exhibit	the	highest	value	of	pi.	LPD	was	performed	using	the	500	
gene	 probes	 with	 the	 greatest	 variation	 in	 expression	 between	 samples	 in	 the	 MSKCC	 dataset.	 The	
process	containing	DESNT	cancers	is	indicated.	b,	List	of	datasets	used	in	LPD	analysis.	The	unique	number	
of	 primary	 cancer	 and	 normal	 specimens	 used	 in	 LPD	 are	 indicated.	 FF,	 fresh	 frozen	 specimen;	 FFPE,	
formalin-fixed	paraffin	embedded	specimen.	The	CancerMap	and	CamCap	were	not	 independent	having	
40	 cancers	 in	 common.	 Clinical	 and	 molecular	 details	 for	 the	 CancerMap	 dataset	 are	 given	 in	
Supplemental	Table	4	and	Supplemental	Data	File	2.	Clinical	details	for	samples	from	other	datasets	used	
in	 this	 study	 can	 be	 found	 in	 Supplemental	 Data	 File	 3.	 	 c,	 Correlations	 of	 average	 levels	 of	 gene	
expression	 between	 cancers	 designated	 as	 DESNT.	 All	 six	 comparisons	 for	 the	 MSKCC,	 CancerMap,	
Stephenson	 and	 Klein	 datasets	 are	 shown.	 The	 expression	 levels	 of	 each	 gene	 have	 been	 normalised	
across	all	samples	to	mean	0	and	standard	deviation	1.	d,	Kaplan-Meier	PSA	failure	plots	for	the	MSKCC,	
CancerMap	and	Stephenson	datasets.		
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Figure	 2.	 Genes	 commonly	 down-regulated	 in	 DESNT	 poor	 prognosis	 prostate	 cancer.	 a,	 Number	 of	
genes	 with	 significantly	 altered	 expression	 in	 DESNT	 cancers	 compared	 to	 non-DESNT	 cancers	 (P<0.01	
after	 correction	 for	 False	Discovery	Rate).	 	 45	 genes	had	 lower	 expression	 in	DESNT	 cancers	 in	 all	 four	
expression	microarray	datasets,	based	on	a	stringency	requirement	of	being	down-regulated	in	at	least	80	
of	100	independent	LPD	runs.	b,		List	of	the	45	genes	according	to	biological	grouping.	Previous	published	
evidence	is	represented	as	superscripts	and	the	supporting	references	are	provided	in	Supplemental	Table	
1.	 Encoded	protein	 functions	 are	 shown	 in	 Supplemental	 Table	 5.	 	 Although	 some	of	 the	 45	 genes	 are	
preferentially	expressed	 in	stromal	tissue	we	found	no	correlation	between	stromal	content	and	clinical	
outcome	 in	 both	 the	 CancerMap	 and	CamCap	patient	 series,	where	 data	 on	 cellular	 composition	were	
available.	 When	 patients	 were	 stratified	 into	 two	 groups	 (above	 and	 below	 median	 stromal	 content)	
Kaplan-Meier	plots	 failed	 to	show	outcome	difference	 for	both	 the	CancerMap	 (Log-rank	 test,	p=0.159)	
and	 CamCap	 (p=0.261)	 patient	 series.	 	 c.	 Relationship	 between	 the	 genes	 in	 published	 poor	 prognosis	
signatures	for	prostate	cancer	and	the	DESNT	classification	for	human	prostate	cancer,	represented	as	a	
circos	plot.	Links	to	the	45	commonly	down-regulated	genes	are	shown	in	brown.		References	quoted	in	
the	circos	plot	are	 listed	 in	 the	Supplemental	 Information	and	detailed	gene	relationships	are	shown	 in	
Supplemental	Data	File	1.		
Figure	3.		Analysis	of	outcome	for	DESNT	cancers	identified	by	RF	classification.	(a-e)	Kaplan-Meier	PSA	
failure	plots	 for	 the	MSKCC	 (a),	CancerMap	 (b),	 Stephenson	 (c),	CamCap	 (d)	and	TCGA	 (e)	datasets.	For	
each	dataset	the	cancers	assigned	to	DESNT	using	the	20	gene	RF	classifier	are	compared	to	the	remaining	
cancers.	The	number	of	cancers	 in	each	group	 is	 indicated	 in	 the	bottom	right	corner	of	each	plot.	The	
number	of	cancers	with	PSA	failure	is	indicated	in	parentheses.		Multivariate	analyses	were	performed	as	
described	 in	 the	Methods	 for	 the	MSKCC	 (f),	 CancerMap	 (g),	 Stephenson	 (h),	 CamCap	 (i)	 and	 TCGA	 (j)	
datasets.	Pathological	Stage	covariates	for	MSKCC	and	Stephenson	datasets	did	not	meet	the	proportional	
hazards	 assumptions	 of	 the	 Cox	 model	 and	 have	 been	 modelled	 as	 time-dependent	 variables,	 as	
described	in	the	Methods.	
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Figure	4.	Comparison	of	RF-DESNT	and	non-RF-DESNT	cancers	in	The	Cancer	Genome	Atlas	dataset.	A	20	
gene	random	forest	(RF)	classifier	was	used	to	identify	DESNT	cancers	(designated	RF-DESNT	cancers).	The	
types	of	genetic	alteration	are	shown	for	each	gene	(mutations,	fusions,	deletions,	and	overexpression).	
Clinical	parameters	including	biochemical	recurrence	(BCR)	are	represented	at	the	bottom	together	with	
groups	for	iCluster,	methylation,	somatic	copy	number	alteration	(SVNA)	and	mRNA[13].	When	mutations	
and	 homozygous	 deletions	 for	 each	 gene	 were	 combined	 RF-DESNT	 cancers	 contained	 an	 excess	 of	
genetic	 alterations	 in	BRCA2	 (P	=	0.021,	 χ²	 test)	 and	TP53	 (P	=	0.0038),	 but	 after	 correcting	 for	multiple	
testing	these	differences	were	not	significant	(P	>	0.05).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	1:	Poor	clinical	outcome	of	patients	with	DESNT	cancer	
	
For	 each	 dataset	 comparisons	 were	 made	 between	 PSA	 failures	 reported	 for	 DESNT	 and	 non-DESNT	
cancers.		LPD,	Latent	Process	Decomposition;	RF,	Random	Forest.	For	LPD	the	log-rank	P-values	represent	
the	 modal	 LPD	 run	 selected	 from	 the	 100	 independent	 LPD	 runs	 as	 described	 in	 the	 Methods.	 For	
multivariate	analyses	Gleason	sum,	PSA	at	diagnosis	and	Pathological	Stage	are	 included	for	all	datasets	
with	the	exception	of	the	TCGA	dataset	where	only	Gleason	sum	and	Clinical	Stage	data	were	available.		
The	full	analyses	are	presented	in	Fig.	3	and	Supplemental	Fig.	3.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	 	
Latent	Process	Decomposition	
Dataset	 Univariate	p-value	 Multivariate	p-value	
MSKCC	 2.65×10−5	 3.27×10−1	
CancerMap	 2.98×10−8	 3.66×10−3	
Stephenson	 4.28×10−5	 1.83×10−4	
CamCap	 1.22×10−3	 2.90×10−2	
Random	Forest	
Dataset	 Univariate	p-value	 Multivariate	p-value	
MSKCC	 1.85×10−3	 6.05×10−1	
CancerMap	 4.80×10−4	 1.45×10−2	
Stephenson	 1.75×10−4	 4.56×10−4	
CamCap	 1.61×10−5	 1.31×10−4	
TCGA	 5.41×10−4	 2.59×10−2	
